(EHAB) Enhabit - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022
EHAB: Home Health, Hospice Services
Enhabit, Inc. (NYSE: EHAB) is a leading provider of home health and hospice services across multiple states in the United States. The company offers comprehensive home health services, including patient education, pain management, and skilled nursing care, designed to help patients recover or manage chronic conditions in the comfort of their homes. These services are cost-effective and provide patients with a comfortable alternative to institutional care.
Enhabits hospice services focus on providing compassionate care to terminally ill patients and their families. The interdisciplinary approach includes medical, emotional, and spiritual support, ensuring comprehensive care that addresses the full spectrum of patient needs.
Formerly known as Encompass Health Home Health Holdings, Inc., Enhabit rebranded in March 2022. Founded in 1998 and headquartered in Dallas, Texas, the company has established a significant presence with numerous locations, enabling it to serve a broad patient base effectively.
3-Month Forecast: Based on technical and fundamental analysis, Enhabits stock is expected to show a neutral to slightly bearish trend. The stock is currently consolidating, with support near the SMA 200 (8.29) and resistance at the SMA 50 (8.13). The low ATR (0.28) indicates moderate volatility, and the average volume of 267,020 suggests limited liquidity. Fundamental analysis reveals a negative RoE (-20.60%) but attractive valuations with a P/B of 0.72 and P/S of 0.39. Investors should monitor upcoming earnings reports for signs of profitability improvement, which could influence the stocks direction.
Additional Sources for EHAB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EHAB Stock Overview
Market Cap in USD | 403m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2022-07-01 |
EHAB Stock Ratings
Growth 5y | -65.0% |
Fundamental | -47.0% |
Dividend | 0.0% |
Rel. Strength Industry | -21.8 |
Analysts | 3.33/5 |
Fair Price Momentum | 6.69 USD |
Fair Price DCF | 21.78 USD |
EHAB Dividends
No Dividends PaidEHAB Growth Ratios
Growth Correlation 3m | 53.9% |
Growth Correlation 12m | -65.9% |
Growth Correlation 5y | -90.2% |
CAGR 5y | -32.52% |
CAGR/Max DD 5y | -0.45 |
Sharpe Ratio 12m | -0.09 |
Alpha | -29.22 |
Beta | 0.60 |
Volatility | 54.69% |
Current Volume | 323.6k |
Average Volume 20d | 312.5k |
As of March 15, 2025, the stock is trading at USD 8.56 with a total of 323,559 shares traded.
Over the past week, the price has changed by +0.35%, over one month by -1.61%, over three months by +0.47% and over the past year by -21.11%.
Probably not. Based on ValueRay Fundamental Analyses, Enhabit (NYSE:EHAB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -46.98 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EHAB as of March 2025 is 6.69. This means that EHAB is currently overvalued and has a potential downside of -21.85%.
Enhabit has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold EHAB.
- Strong Buy: 1
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, EHAB Enhabit will be worth about 7.2 in March 2026. The stock is currently trading at 8.56. This means that the stock has a potential downside of -15.54%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.9 | 4% |
Analysts Target Price | 8.9 | 4% |
ValueRay Target Price | 7.2 | -15.5% |